Oral drug delivery system

• US 8,354,124 B2
• Filed: 02/03/2012
• Issued: 01/15/2013
• Est. Priority Date: 12/13/2002
• Status: Expired due to Fees

• Current Assignee: DURECT Corporation
• Original Assignee: DURECT Corporation
• Inventors: Yum, Su Il, Schoenhard, Grant, Tipton, Arthur J., Gibson, John W., Middleton, John C.
• Primary Examiner(s): FUBARA, BLESSING M
• Application Number:
  US13/366,164
• Publication Number:
  US 20120135072A1
• Time in Patent Office: 347 Days
• Field of Search: 424/456, 424/400, 424/451, 424/1.25, 514/960, 514/159, 514/282, 514/778
• US Class Current: 424/485
• CPC Class Codes: A61K 31/4458 only substituted in position 2, e.g. methylphenidate
• CPC Class Codes: A61K 31/485 Morphinan derivatives, e.g. morphine, codeine
• CPC Class Codes: A61K 47/14 Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• CPC Class Codes: A61K 47/26 Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• CPC Class Codes: A61K 47/38 Cellulose; Derivatives thereof
• CPC Class Codes: A61K 9/0053 Mouth and digestive tract, i.e. intraoral and peroral administration rectal administration A61K9/0031
• CPC Class Codes: A61K 9/48 Preparations in capsules, e.g. of gelatin, of chocolate A61K9/0004 takes precedence; bite capsules A61K9/0056
• CPC Class Codes: A61K 9/4825 Proteins, e.g. gelatin gelatin capsule shells with substantial amounts of other macromolecular substances A61K9/4816
• CPC Class Codes: A61K 9/4858 Organic compounds
• CPC Class Codes: A61K 9/4866 Organic macromolecular compounds
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids
• CPC Class Codes: A61P 25/20 Hypnotics; Sedatives
• CPC Class Codes: A61P 25/26 Psychostimulants, e.g. nicotine, cocaine
• CPC Class Codes: A61P 25/36 Opioid-abuse
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Dosage forms and drug delivery devices suitable for administration of pharmaceutical compounds and compositions, including the oral drug administration of compounds.

Claims

1. A formulation comprising:

a drug selected from buprenorphine, butorphanol, hydrocodone, hydromorphone, levorphanol, meperidine, methadone, morphine, oxycodone, oxymorphone, and tramadol, or a pharmacologically effective salt thereof;

sucrose acetate isobutyrate (SAIB);

a cellulose acetate butyrate (CAB) having a number average molecular weight ranging from 66,000 Daltons to 83,000 Daltons; and

a solvent in which the CAB is soluble.

2. The formulation of claim 1, further comprising a member selected from caprylic/capric triglyceride, isopropyl myristate (IPM), ethyl oleate, dimethyl phthalate, and benzyl benzoate.

3. The formulation of claim 1, further comprising butylhydroxyl toluene.

4. The formulation of claim 1, wherein the formulation comprises:

from about 20 weight percent to about 90 weight percent of the SAIB;

from about 1 weight percent to about 8.6 weight percent of the CAB; and

from about 20 weight percent to about 50 weight percent of the solvent.

5. The formulation of claim 1, wherein the formulation comprises:

from about 30 weight percent to about 70 weight percent of the SAIB;

from about 1 weight percent to about 8.6 weight percent of the CAB; and

from about 25 weight percent to about 48 weight percent of the solvent, wherein the solvent comprises triacetin or ethyl lactate.

6. The formulation of claim 5, wherein the formulation is contained in a capsule comprising gelatin or hydroxyl propylmethyl cellulose.

7. The formulation of claim 6, wherein the formulation further comprises butylhydroxyl toluene.

8. The formulation of claim 1, wherein the drug comprises oxycodone or a pharmacologically effective salt thereof.

9. The formulation of claim 1, wherein the drug comprises a pharmacologically effective salt of oxycodone.

10. A formulation comprising:

an opioid;

sucrose acetate isobutyrate (SAIB);

a cellulose acetate butyrate (CAB) having a number average molecular weight ranging from 66,000 Daltons to 83,000 Daltons; and

a solvent in which the CAB is soluble.

11. The formulation of claim 10, further comprising a member selected from caprylic/capric triglyceride, isopropyl myristate (IPM), ethyl oleate, dimethyl phthalate, and benzyl benzoate.

12. The formulation of claim 10, further comprising butylhydroxyl toluene.

13. The formulation of claim 10, wherein the formulation comprises:

from about 20 weight percent to about 90 weight percent of the SAIB;

from about 1 weight percent to about 8.6 weight percent of the CAB; and

from about 20 weight percent to about 50 weight percent of the solvent.

14. The formulation of claim 10, wherein the formulation comprises:

from about 30 weight percent to about 70 weight percent of the SAIB;

from about 1 weight percent to about 8.6 weight percent of the CAB; and

from about 25 weight percent to about 48 weight percent of the solvent, wherein the solvent comprises triacetin or ethyl lactate.

15. The formulation of claim 14, wherein the formulation is contained in a capsule comprising gelatin or hydroxyl propylmethyl cellulose.

16. The formulation of claim 15, wherein the formulation further comprises butylhydroxyl toluene.

17. A formulation comprising:

oxycodone;

sucrose acetate isobutyrate (SAIB);

a cellulose acetate butyrate (CAB) having a number average molecular weight ranging from 66,000 Daltons to 83,000 Daltons; and

a solvent in which the CAB is soluble.

18. The formulation of claim 17, further comprising a member selected from caprylic/capric triglyceride, isopropyl myristate (IPM), ethyl oleate, dimethyl phthalate, and benzyl benzoate.

19. The formulation of claim 17, further comprising butylhydroxyl toluene.

20. The formulation of claim 17, wherein the formulation comprises:

from about 20 weight percent to about 90 weight percent of the SAIB;

from about 1 weight percent to about 8.6 weight percent of the CAB; and

from about 20 weight percent to about 50 weight percent of the solvent.

21. The formulation of claim 17, wherein the formulation comprises:

from about 30 weight percent to about 70 weight percent of the SAIB;

from about 1 weight percent to about 8.6 weight percent of the CAB; and

from about 25 weight percent to about 48 weight percent of the solvent, wherein the solvent comprises triacetin or ethyl lactate.

22. The formulation of claim 21, wherein the formulation is contained in a capsule comprising gelatin or hydroxyl propylmethyl cellulose.

23. The formulation of claim 22, wherein the formulation further comprises butylhydroxyl toluene.

24. The formulation of claim 17, wherein the solvent is selected from triacetin and ethyl lactate.

25. A method of preparing a formulation comprising:

an opioid;

sucrose acetate isobutyrate (SAIB);

a cellulose acetate butyrate (CAB) having a number average molecular weight ranging from 66,000 Daltons to 83,000 Daltons; and

a solvent in which the CAB is soluble,

the method comprising;

mixing the SAIB, the CAB, the solvent, and the opioid to form the formulation.

26. The method of claim 25, wherein the mixing comprises combining the SAIB, the CAB, the solvent, the opioid, and a member selected from caprylic/capric triglyceride, isopropyl myristate (IPM), ethyl oleate, dimethyl phthalate, and benzyl benzoate.

27. The method of claim 25, wherein the formulation comprises:

from about 20 weight percent to about 90 weight percent of the SAIB;

from about 1 weight percent to about 8.6 weight percent of the CAB; and

from about 20 weight percent to about 50 weight percent of the solvent.

28. The method of claim 25, further comprising encapsulating the formulation in a capsule.

29. The method of claim 28, wherein the capsule comprises a capsule comprising gelatin or hydroxyl propylmethyl cellulose, wherein the formulation comprises:

from about 30 weight percent to about 70 weight percent of the SAIB;

from about 1 weight percent to about 8.6 weight percent of the CAB; and

from about 25 weight percent to about 48 weight percent of the solvent, wherein the solvent comprises triacetin or ethyl lactate.

30. The method of claim 29, wherein the formulation further comprises butylhydroxyl toluene.

31. The method of claim 25, wherein the opioid comprises oxycodone or a pharmacologically effective salt thereof.